← Leaderboards
Kimberly Anne Johnston
Innovative Biotherapies, Inc.
$3,416,648
Attributed
$3,416,648
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,416,648 · 2
By mechanism
R44$2,827,948 · 1
R43$588,700 · 1
Top collaborators
No co-investigators on record.
Most similar at Innovative Biotherapies, Inc.
Same institution · by research overlap
- Christopher Pino$2,536,223
- Angela J Westover$2,300,967
Others in their field
Top investigators on “Myocardial”
- Judith S Hochman · New York University School Of Medicine$121,330,744
- Paul M. Ridker · Brigham And Women'S Hospital$57,568,630
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$57,170,001
- Pamela Susan Douglas · Duke University$51,876,470
- Julie E Buring · Brigham And Women'S Hospital$46,077,806
- Walter N Kernan · Yale University$42,197,025
Research focus
MyocardialRenal FunctionImmunoregulationMembranePre-ClinicalPumpCitratesImmune SystemInnovationLeukocytesDevicesOrganPreclinical StudyProceduresAcuteCardiovascular DiseasesEnvironmentFunctional DisorderCalciumInflammationKidneyCardiacClinical TrialsSafety
Grant awards (3)
Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients$1,513,922
R44 · FY2025 · HL · contact PI
Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients$1,314,026
R44 · FY2024 · HL · contact PI
L-MOD Therapy: Leukocyte Immunomodulation during Cardiopulmonary Bypass$588,700
R43 · FY2015 · HL · contact PI